Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, Beijing 100029, China.
Chin Med J (Engl). 2013 Mar;126(6):1033-8.
Catheter ablation for atrial fibrillation (AF) has been demonstrated to be effective in a subsets of patients with AF. However, very few data are available in regard to patients with prior history of stroke undergoing catheter ablation. This study aimed to investigate the outcome of catheter ablation in AF patients with prior ischemic stroke.
Between January 2008 and December 2011, of 1897 consecutive patients who presented at Beijing An Zhen Hospital for treatment of drug-refractory AF, 172 (9.1%) patients in the study population had a history of ischemic stroke. All patients underwent catheter ablation and were followed up to assess maintenance of sinus rhythm and recurrence of symptomatic stroke.
Among these 1897 patients, 1768 (93.2%) who had complete follow-up information for a minimum of six months were included in the final analysis. Patients in the stroke group (group I) and the no-stroke group (group II) were similar in regards to gender, body mass index (BMI), history of diabetes, type of AF, and left atrial size. The patients in group I were older than those in group II, and had a higher incidence of hypertension, chronic heart failure, lower left ventricular ejection fraction (LVEF), and higher CHADS2 scores. Six months after ablation, 107 (68.6%) patients in group I and 1403 (87.1%) in group II had discontinued warfarin treatment (P < 0.001). During a median follow-up of (633 ± 415) days, 65 patients in the group I and 638 in group II experienced AF recurrence, and five patients in group I and 28 in group II developed symptomatic stroke. The rates of AF recurrence and recurrent stroke were similar between group I and group II (41.7% vs. 39.6%, P = 0.611; 3.2% vs. 1.7%, P = 0.219; respectively).
Catheter ablation of AF in patients with prior stroke is feasible and efficient.
导管消融术已被证实对某些房颤(AF)患者有效。然而,对于既往有中风病史的患者接受导管消融术的数据非常有限。本研究旨在探讨既往有缺血性中风病史的 AF 患者导管消融术的结果。
2008 年 1 月至 2011 年 12 月,在 1897 例因药物难治性 AF 就诊于北京安贞医院的连续患者中,172 例(9.1%)患者有缺血性中风病史。所有患者均接受导管消融术,并进行随访以评估窦性心律的维持和症状性中风的复发情况。
在这 1897 例患者中,有 1768 例(93.2%)具有至少 6 个月的完整随访信息,被纳入最终分析。中风组(I 组)和无中风组(II 组)在性别、体重指数(BMI)、糖尿病史、AF 类型和左心房大小方面相似。I 组患者年龄大于 II 组,且高血压、慢性心力衰竭、左心室射血分数(LVEF)较低和 CHADS2 评分较高的发生率较高。消融术后 6 个月,I 组 107 例(68.6%)和 II 组 1403 例(87.1%)患者停止使用华法林治疗(P < 0.001)。在中位数(633 ± 415)天的随访期间,I 组有 65 例和 II 组有 638 例患者出现 AF 复发,I 组有 5 例和 II 组有 28 例患者发生症状性中风。I 组和 II 组的 AF 复发和复发性中风的发生率相似(41.7% vs. 39.6%,P = 0.611;3.2% vs. 1.7%,P = 0.219)。
既往有中风病史的 AF 患者行导管消融术是可行和有效的。